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HLA class II antigens are developmentally regulated, polymorphic, cell surface 
glycoproteins that function as restriction elements in cell-to-cell interactions in 
the immune response (1). They are heterodimeric, composed of ~ and 13 chains 
of about  34  and  29  kilodaltons,  respectively  (2).  The  HLA-DR  /3  chain  is 
polymorphic, whereas the DR a  chain has little or no polymorphism; both DQ a 
and/3 chains exhibit polymorphism (2). The regions of class II molecules involved 
in  the  restriction  phenomenon are  unknown.  There  are  at  least  three  well- 
defined class  II antigens, HLA-DR, -DQ (formerly MB/DC/DS), and -DP (for- 
merly SB),  each with different ~  and/3 chains. Southern blots made with DR, 
DQ, and DP ~ and 13 cDNA probes suggest that the HLA region contains at least 
twice as many class  II genes as are necessary to code for the three well-defined 
dimers (3), but it is not known how many or which of these genes are expressed. 
Class II molecules are present on cells involved in the immune response, including 
B cells,  macrophages, and activated T  cells.  They are also expressed transiently 
on erythroid and granulocytic precursor cells (4) and on nonhematopoietic cells 
(5,  6),  suggesting that class  II molecules may have a  more general role in cell- 
cell  interactions  in  development and,  also,  that  nonlymphoid cells  may have 
functional roles in the immune response.  In addition to developmentally regu- 
lated expression, class  II gene expression is modulated in some cells by agents 
such as 3' interferon (7) and prostaglandins (8). 
One  approach  to  studying  questions  of major  histocompatibility complex 
(MHC) j structure and regulation is to isolate and characterize immunoselected 
mutants (9).  We  previously isolated a  class  II  regulatory mutant,  6.1.6  (10), 
which appears to have a defect in a positive transactive regulator of transcription 
of class II genes (11,  12). In the present studies, we have used mutagenesis with 
the alkylating agent ethyl methanesulfonate (EMS) and the anti-HLA-DR3 mon- 
oclonat  antibody  (mAb)  16.23  (13)  to  isolate  a  large  number  of HLA-DR3 
mutants. To simplify the subsequent analysis, the selection was carried out on a 
previously isolated deletion mutant missing all DR and DQ o~ and/3 genes on one 
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haplotype.  Several  of the  mutants  isolated  were  found  to  have  defects  in  the 
epitope reactive with  16.23.  Others have defects in several different steps in the 
pathway  leading  to  expression  of the  DR  a  or  /3  genes,  including  DR  gene 
transcription  and mRNA  processing.  These mutants allowed us to study various 
aspects of the regulation of the class II gene expression and the structure of class 
II gene products. 
Materials  and  Methods 
Cell  Lines.  Deletion  mutants  8.1.6  and  9.28.6  were  derived  from  T5-1,  a  clonal 
derivative of the B cell line PGLC33H, which is DP4 positive and has the HLA haplotypes 
DQ1,  DR1,  B27,  CW1,  A2 and  DQ2,  DR3,  B8,  A1  (10).  8.1.6  is an  immunosetected 
deletion mutant of T5-1 that has lost the cis specificities DQ1 and DR1 (10). By Southern 
blotting it is missing all DQ and DR genes on the DQ1,  DR1, B27, CW1, A2 haplotype 
(3). 9.28.6 is an immunoselected deletion mutant ofT5-1 ; it is missing all HLA specificities 
on the  DQ2,  DR3,  B8, A1  haplotype and,  by Southern blotting,  all  class I, II, and  III 
genes on that haplotype (3,  14). The DR null mutant 4.36.84 was derived from 9.28.6 by 
mutagenesis  with  diepoxy  octane  and  selection  with  the  anti-HLA-DR  monomorphic 
antibody, VI. 15 (see Results). 
Antibodies Against HLA Class 1I.  mAb 16.23 has been shown in population and family 
studies to be HLA-DR3 specific, but it reacts with some HLA-Dw/DRw6 individuals as 
well (13). mAbs VI.15 (14), HB10A (15), L227 (16), L243 (16), LKT (17), and DA6.147 
(18) are class  II monomorphic antibodies  that are  thought to react with  HLA-DR and 
possibly with  other  class  II antigens;  further  characterization  of the  class  II molecules 
reactive  with  these  antibodies  is presented  in  Results.  mAb B7/21.2  reacts with  a  cell 
surface class II molecule structurally distinct from HLA-DR and -DQ (19); transfection 
experiments  have established  that  it reacts with  HLA-DP (20).  mAb Genox  3.53  is an 
allospecific antibody recognizing DQ 1 (21). mAbs VI. 15 and L243 react only with dimeric 
HLA-DR,  whereas  HB10A,  L227,  and  LKT  react  with  dimer  as  well  as  with  DR  /3 
monomer.  DA6.147  reacts  with  HLA-DR and  with  monomeric  DR  c~.  All  mAb were 
concentrated 10-20-fold from hybridoma supernatants by (NH4)~SO4 precipitation. 
Mutagenesis  and Mutant Isolation.  Cells were mutagenized with  100 ~g/ml EMS  for 
24 h, washed, and grown in normal medium for 7 d, then  used for selection.  Selection 
was  by  brief exposure  to  an  mAb,  followed  by  complement,  followed  by  cloning  as 
previously described (22). 
Quantitative Cell Surface Antibody Binding.  This was done as described (14). ~25I-labeled 
protein  A  or ~25I-]abeled  187.1,  which is a  rat mAb with specificity for mouse K chains 
(23), were used as second-step reagents. All antibodies were used in saturating amounts. 
Class II Gene Clones.  The cDNA probes used encode the entire DR c~ (24) and/3 (25) 
chains. 
Northern and Southern Blot Analysis.  These methods have been described (12).  Each 
Northern  blot was repeated  two to three  times and the blots shown are representative. 
Densitometry was performed  using an Ultrascan  densitometer  (LKB Instruments,  Inc., 
Gaithersburg,  MD).  The  band  intensities  shown  are  ratios  of the  peak  height  of the 
mutant compared with  that of 8.1.6,  normalized to the  ratio of peak heights of class I 
mRNA. 
Western Blot Analysis.  Cell lysates were prepared by solubilizing cells at a concentration 
of 5  X  10 7 cells/ml in  1.5% Nonidet P-40 (NP-40) in  10 mM Tris-HCl, pH 7.8, with 0.2 
mM  phenylmethylsulfonylfluoride.  Lysates  were  diluted  with  an  equal  volume  of 2x 
sodium  dodecyl sulfate  (SDS) sample buffer (2.5%  SDS final) and  heated  for 2  min at 
100 ° C. In those experiments in which detection of undissociated dimers was desired, the 
sample, containing only 0.2-0.4%  SDS, was not boiled. Samples were electrophoresed in 
12% SDS-polyacrylamide gel electrophoresis (PAGE), and then electrophoretically trans- 
ferred to a  nitrocellulose filter for 2  h  at 50 V; 0.1%  SDS was included in the transfer 
buffer.  The  filter  was  incubated  for  1 h  at  4°C  with  phosphate-buffered  saline  (PBS) 
containing 25% fetal calf serum (FCS). PIOUS  ET  AL.  1195 
The filters were reacted for 2 h with saturating amounts of first antibody (HB10A or 
DA6.147,  which,  respectively,  recognize DR  /3 and  a  chains),  for  1 h  with  saturating 
amounts of second antibody (rabbit  anti-mouse  IgG), and  for  1 h  with  subsaturating 
amounts of 125I-protein A at 106 cpm/ml. Anti-actin antibody was added with the HB10A 
or DA6.147 antibody to provide an internal control for the amount of cell extract in each 
lane.  Preliminary experiments established that under these conditions, the band intensities 
were proportional to the amount of antigen in the extract. After each incubation, filters 
were washed three times for 5 min each with 100 ml PBS containing 5% FCS and 0.05% 
NP-40. Autoradiographs were prepared using Kodak X-Omat AR film at -70°C. Densi- 
tometry was performed as for the Northern blots except that the ratios of band intensities 
of mutant to 8.1.6 were normalized to the ratio of the actin band intensities. 
Results 
Mutant Selection  and Screening.  A  deletion mutant ofT5-1, 8.1.6, which had 
lost  all  the  DR  and  DQ  a  and  /3  genes  on  the  DQ1,  DR1,  B27,  CW1,  A2 
haplotype, was chosen as a  target cell for selection to simplify the interpretation 
of HLA-DR protein and mRNA levels in any mutants isolated. After mutagenesis 
of 8.1.6  with  EMS,  immunoselection was carried out with  the  HLA-DR3 mAb 
16.23, at two levels, one approximately saturating (stringent selection), and the 
other, less than saturating (relaxed selection) (Table I). Relaxed selection maxi- 
mizes the likelihood that mutants which retain some capacity to bind the selecting 
antibody will survive selection, but it also increases the likelihood that nonmutant 
cells  will  survive  (26).  Colonies  arising  after  selection  were  screened  for  cell 
surface binding of antibody 16.23 by radioimmune binding assay. Only colonies 
with binding ratios <0.5 were studied further (23 of the 62 tested clones). 
The  mutant  frequencies  for clones  with  binding  ratios  <0.5,  corrected  for 
cloning efficiency, were  1.6  ×  10  -4 and  3  ×  10  -4 for the stringent and relaxed 
selections, respectively. These mutant frequencies are similar to those of class I 
mutants  induced  by  comparable  exposure  to  EMS  (26).  Given  the  mutant 
frequencies,  the probability that any mutant contains more than one mutation 
affecting an HLA-DR gene is equal to the observed mutant frequency multiplied 
by the number of HLA-DR genes, or ~0.001. 
Surface Binding Patterns of Antibodies  16.23,  VL 15, and HB IOA Divide Mutants 
into  Two Classes.  To define  the  phenotype of these  mutants  further,  the  cell 
TABLE  I 
Selection of 16.23 Mutants 
16.23 Anti-  No. of surviv-  Tube No.  body  ing colonies 
No. of colonies with bind- 
ing ratios* of: 
<0.1  0.1-0.5  >0.5 
ul 
1  500  21  3  5  8 
2  250  64  6  9  31 
EMS-mutagenized 8.1.6 cells, 5 ×  10  s per tube, were immunoselected 
with  16.23 hybridoma supernatant  in  the  volumes shown and  with 
complement, and were then cloned as described. 
* Binding ratio was calculated as (cpm bound by surviving clone -  cpm 
bound  by negative control/(cpm  bound  by  8.1.6  -  cpm  bound  by 
negative control). For details on the binding assay, see Table II. 1196  HLA  CLASS  II  POINT  MUTANTS 
surface binding of various mAb, including 16.23 and several monomorphic anti- 
HLA-DR antibodies, was examined.  15 mutants were studied in detail. A striking 
feature of these data  is  that  the mutants  fall into two distinct,  nonoverlapping 
groups with  respect  to the pattern  of cell surface  binding of 16.23  and VI.15 
(Table  II).  One  group  consists of seven  mutants  (9.2.3,  9.5.3,  9.10.3,  9.25.3, 
9.26.3, 9.28.3, and 9.29.3), which had markedly reduced or absent 16.23 binding 
but  normal  or  near  normal  binding  of the  HLA-DR  monomorphic  antibody 
VI. 15.  We interpret this pattern as indicative of expression on the cell surface 
of a normal quantity of HLA-DR3  antigen, as measured by VI. 15 binding, but 
with  an  alteration  in  the  epitope  recognized  by  the  16.23  antibody  (epitope 
defective). The other broad class consists of eight mutants with parallel reductions 
in binding of 16.23 and VI. 15. The parallel reduction in cell surface binding of 
16.23  and  VI.15,  as  well as  studies to be  described,  indicate that  these  latter 
mutants  have  a  reduced  amount  of HLA-DR3  antigen  expressed  at  the  cell 
surface (expression  defective).  Cell surface binding of 16.23,  VI.15, and  L243 
in  expression-defective  mutants  varied  from  at  or  near  background  (mutant 
9.22.3)  to  ~40%,  close to the  upper range of binding considered mutant;  the 
binding of H B 10A, another class II monomorphic antibody, paralleled but was 
in most cases somewhat higher than that of VI. 15. 
In contrast to the  16.23 and VI.15 binding, the binding of two other class II 
TABLE  II 
Cell Surface Antibody Binding by 16.23 Mutants 
Mutant  Antibody binding ratio (xl00) 
clone  16.23  VI.15  L243  HB10A  LKT  L227  B7/21.2 
(8.1.6)  0oo)  (1oo)  (loo)  (loo)  (loo)  (lOO)  (loo) 
(6.1.6)  15_+3  8_+3  11_+1  4_+1  12_+4  9_+2  10 
9.2.3  3  73  ND  ND  ND  ND  ND 
9.5.3  0  102  ND  65  88  100  ND 
9.10.3  0  73  ND  82  97  101  ND 
9.25.3  0  102  ND  ND  ND  ND  ND 
9.26.3  12  t06  ND  ND  ND  ND  ND 
9.28.3  0  82  ND  ND  ND  ND  ND 
9.29.3  7  97  ND  86  ND  ND  ND 
9.4.3  9  13  11  34  55  43  117 
9.7.3  28  36  ND  33  ND  ND  ND 
9.12.3  15  25  20  26  75  58  122 
9.13.3  25  22  ND  29  ND  ND  ND 
9.15.3  17  20  17  34  55  41  105 
9.20.3  41  31  32  ND  ND  ND  137 
9.22.3  1  3  0  6  45  50  87 
9.27.3  7  12  ND  24  ND  ND  ND 
Binding ratio:  (cpm  bound  by mutant  -  cpm  bound  by negative  control)/(cpm  bound  by  8.1.6  - 
cpm bound by negative control). The negative control is 6.1.6, a regulatory mutant of T5-1 that has 
a reduction of ~99.5% in expression of class I1 molecules (10,  12). Binding ratio of 6.1,6 (cpm bound 
by 6.1.6)/(cpm bound by 8.1.6). The binding ratios represent the median values from three or more 
independent  assays.  The  standard  errors given  for  6.1.6 are representative.  The  binding  to 6.1.6 
reflects nonspecific binding to the assay tubes. PIOUS  ET  AL.  1197 
monomorphic antibodies,  LKT and  L227,  was reduced  at  most to 40%  of the 
parental  value  in  the  expression-defective mutants,  even  in  9.22.3,  which  had 
>94%  reduction  in  16.23,  VI.15,  L243,  and  HB10A  binding.  These  findings 
suggest  that  L227  and  LKT  might  recognize  at  least  two  class  II  surface 
molecules, only one of which is affected in these mutants. 
mAbs LKT and L227 Bind to HLA-DP as Well as HLA-DR.  The identity of the 
other  molecule  besides  HLA-DR  recognized  by  LKT  and  L227  was  studied 
using another set of mutants derived  from T5-1.  Mutant  9.28.6  is an immuno- 
selected,  hemizygous deletion  mutant  of T5-1  that  has lost the complete ttLA 
complex on  the  DR3  side (3,  14).  Selection  on  9.28.6  with the  anti-DR  mono- 
morphic antibody VI. 15 yielded the DR null mutant 4.36.84 (Table III); selection 
on  4.36.84  was then  carried  out  with  the anti-DP antibody B7/21.2.  All  three 
mutants  from the  B7/21.2  selection  that  are  B7/21.2  null  (11.6.84,  11.11.84, 
and  11.13.84) also lost LKT and L227 binding, indicating that loss of LKT and 
L227  binding  is  coincident  with  loss  of HLA-DP.  The  fact  that  Genox  3.53 
binding was retained  in these mutants argues against a deletion extending from 
HLA-DP to -DQ.  Thus,  LKT  and  L227  must detect a  determinant  shared  by 
DR and DP/3 chains. 
Expression-defective Mutants Have Alterations  or Reductions in Either DR 0¢ or t3 
mRNA, But Not in Both.  To investigate the nature of the lesions in mutants with 
reduced  levels of HLA-DR3  at the  cell  surface,  Northern  blotting with  HLA- 
DR  c~ and  /3 cDNA  probes  was  used  to  determine  levels of DR a  and/3  chain 
mRNA.  Representative  blots  are  shown  in  Figs.  1  and  2.  All  the  expression- 
defective mutants had a clear reduction or alteration in either DR a  or/3 mRNA, 
but not in both.  Mutants 9.4.3, 9.15.3, 9.16.3, 9.20.3 (and 9.7.3 and 9.13.3, not 
shown) had reductions  in  DR3/3 mRNA  ranging of 70-95%, whereas their DR 
mRNA  levels  are  essentially  normal.  Mutant  9.22.3,  in  contrast,  had  no 
detectable  DR c~ mRNA  but had normal levels of DR/3 mRNA. Mutant 9.12.3 
had a reduced amount of DR a  mRNA of normal size (1.2 kilobase [kb]), but, in 
addition, had a second band of 2.7 kb, not seen in 8.1.6 or other mutants, which 
hybridized  to  the  DR  a  probe.  Thus,  in  all  the  mutants  that  were  initially 
TABLE III 
Cell Surface Antibody Binding by HLA-DR and -DR, 
Mutants 
-DP Null 
Mutant  Antibody binding ratio (X 100) 
clone  B7/21.2  VI. 15  B 10A  LKT  L227  Genox 
(9.28.6)  (100)  (100)  (100)  (100)  (100)  (100) 
(6.1.6)  14  2  4  9  11  14 
4.36.84  128  0  3  40  18  79 
11.6.84  0  0  0  0  1  133 
11.11.84  0  0  0  0  0  62 
11.13.84  0  0  0  0  1  108 
For details on the binding assay, see legend to Table I1. For the origins of 
the DR null mutant 4.36.84, and the DR and DP null mutants  11.6.84, 
11.11.84, and 11.13.84, see Results. 1198  HLA  CLASS  lI  POINT  MUTANTS 
FICURE  1.  Northern  blot  analysis of 8.1.6  and mutant  RNAs with  DR  a  and/3 and  HLA 
class I cDNA gene probes. The  18 and 28 S ribosomal RNAs can be seen faintly on the DR/3 
blots. The ratios of band intensities of mutants to 8.1.6 for the DR a and 13 mRNA, respectively, 
are:  9.4.3,  0.66 and  0.06;  9.15.3,  0.81  and <0.06;  9.16.3,  1.42 and  0.07;  9.20.3,  1.00  and 
0.21; 9.22.3, <0.06 and 0.72. The alterations in 9.12.3 DR c~ mRNA can be seen more clearly 
in Fig. 2. 
grouped together on the basis of reduced levels of HLA-DR3 protein at the cell 
surface, the reduction can be accounted for by a reduced level or altered size of 
DR ot or/3 mRNA. 
Mutant 9. 22.3 Has a Deletion of the DR a  Gene.  We investigated the possibility 
that  one  or  more  of  the  expression-defective  mutants  resulted  from  gross 
deletions of DR structural genes, which could be detected by Southern blotting 
using DR o~ and/3 cDNA probes. The DR a  probe hybridizes to a  single gene 
(23) that maps to the HLA class II region (27). A DR o~ Bgl II restriction fragment 
length polymorphism (RFLP) has been described; T5-1  is heterozygous for this 
RFLP, with bands of 4.2  and 3.8  kb (Fig.  3A).  8.1.6  is deleted for DQ1  and 
DR1  and had only the 3.8 kb DR a  band.  Mutant 9.22.3, derived from 8.1.6, 
lacked both the 4.2 and the 3.8 kb bands and therefore has undergone deletion 
of the remaining DR ~  gene. Southern blots made with the DR 13 probe were 
more complex, because each haplotype carries  two or more DR /3 genes, and 
haplotypes  may  differ  with  respect  to  the  number  of  DR  /3  genes  carried. 
However, we have previously shown (3) that in 8.1.6 all DR/3 genes on the DR 1 
haplotype of T5-1  are deleted; thus, all bands hybridizing to the DR/3 probe in 
8.1.6  come  from  the  DR3  haplotype.  Fig.  3B  shows  that  all  bands  in  8.1.6 
hybridizing with the DR/3 probe were also present in 9.22.3. Thus, the deletion 
in 9.22.3 does not extend to the closely linked DR 13 gene complex, nor to the 
complement C4 gene (data not shown). No bands hybridizing to the DR/3 probe 
were lost in  the other  DR /3 expression-defective mutants; therefore, of these 
mutants, only 9.22.3  has a  deletion large enough to be detected by Southern PIOUS  ET  AL.  1199 
FIOURE 2.  Northern blot analyses of 8.1.6, 9.12.3, and 9.22.3 RNAs with DR a and ~ gene 
probes. The band intensity ratios for 9.12.3 are: DR a 2.7 kb mRNA, 0.31; 1.2 kb mRNA, 
0.28; DR ~ mRNA, 1.13. 
blotting.  The fact that there was essentially no binding of 16.23,  VI.15,  L243, 
or HB10A to 9.22.3  (Table II), although the deletion did not extend to the DR 
/3 genes, suggests that  DR ~3 subunits do not form noncognate dimers with DQ 
or DP a  chains. 
Methylation  of a  Single  DR  t3  Gene Is Altered  in  Some DR  13 Expression-defective 
Mutants.  Class  II  genes  from  cells  active  in  class  II  gene  transcription  have 
different patterns of cytosine methylation than those from class II nontranscrib- 
ing  cells  (28).  It  was  therefore  of interest  to  determine  whether  there  were 
changes  in  the  patterns  of  methylation  of  DR  /3  genes  in  the  HLA-DR  /3 
expression-defective mutants  described  here.  Southern  blots were  made  from 
Bgl  II-Hpa  II  double  digests  of  DNA  from  8.1.6  and  from  several  DR  /3 
expression-defective mutants,  and  were  hybridized with  a  DR  /3  cDNA  probe 
(Fig. 4). Of the six strongly hybridizing bands seen in the Bgl  II-Hpa II double 
digests, five were identical in 8.1.6 and in all three mutants. The sixth band (5.0 
kb) was present in 8.1.6 and in mutant 9.20.3, but was missing in mutants 9.4.3 
and 9.15.3,  and was replaced in  9.4.3  and 9.15.3  by a  band of 4.6  kb.  Thus, a 
cytosine  in  or  around  one  of the  DR  /3  genes  is  methylated  in  8.1.6,  which 
expresses DR  /3, but  is demethylated in  mutants  9.4.3  and  9.15.3,  which  have 
severe reductions in DR/3 mRNA level. 
Expression-defective  Mutants  Have  Reduced  Levels  of Both  DR  a  and  /3 Protein 
Subunits.  The  reductions  in  DR  a  or  /3  mRNA  in  the  expression-defective 
mutants  and  the  cell  surface  binding  data  predict  that  the  amounts  of the 
corresponding  subunit  proteins  should  also  be  reduced.  To  investigate  this, 1200  HLA  CLASS  It  POINT  MUTANTS 
FIGURE  3.  Southern blot analysis of 8.1.6 and expression-defective  mutants with DR a  and 
/3 gene probes. The restriction fragment sizes were calculated from a Hind Ill digest of lambda 
DNA (not shown). 
FIGURE 4.  Methylation patterns of DR/3 genes in 8.1.6 and in mutants with reduced DR/3 
mRNA levels. The restriction enzymes Hpa  II  and Msp l  recognize the same sequence (5' 
CCGG 3') but differ in that Hpa II will not cut if the internal cytosine is methylated whereas 
Msp I  will cut regardless of the methylation state of the internal cytosine. In the first lane, 
8.1.6 DNA had been digested with Bgl  II plus Msp I; in the other lanes the DNAs had been 
digested with Bg!  It and Hpa It. PIOUS  ET  AL.  1201 
detergent extracts of the cells were boiled and  reduced to dissociate the HLA- 
DR dime'r, then subjected to Western blotting using mAbs DA6.147 and HB 10A 
to  detect  the  DR  a  and  13  subunits,  respectively.  Fig.  5  shows  representative 
Western  blots of detergent extracts  from  equal  numbers  of mutant  and  8.1.6 
cells. The most striking finding from these studies is that the quantities of both 
DR a  and/3 chains were decreased in all the mutants that had reduced expression 
of  HLA-DR3  on  the  cell  surface.  Even  though  in  each  expression-defective 
mutant the defect can be related to a reduced level or alteration in size of either 
DR 0~ or/3 mRNA, but not of both, the levels of both DR a  and/3 subunits were 
reduced  in  all.  The  fact that  all  mutants  with  reductions of either DR  a  or/3 
mRNA  had  reductions  in  both DR  a  and  /3 protein  subunits  suggests  that  the 
protein  product  from  the  unaffected  DR  a  or  /3  gene  must  undergo  rapid 
degradation unless it can form dimers. The apparently greater reduction in DR 
0~  than  /3  subunits  in  all  the  expression-defective mutants  may  reflect affinity 
differences between  DA6.147  and  HB10A for their respective target antigens. 
The instability of HLA-DR  protein  monomers is in  contrast to the stability of 
class I heavy chain monomers, which accumulate intracellularly both in mutants 
with altered heavy chains that are unable to dimerize (26), and in the Daudi cell 
line, which lacks/3z microglobulin (29). 
Epitope-defective  Mutants  Have  Altered  Subunit  Associations.  To  search  for 
further evidence of structural changes in  16.23 epitope mutants, we altered the 
conditions of preparation of the cell sample for Western blots so as to visualize 
the  HLA-DR dimer.  It is known  that  HLA-DR antigen  migrates as a  dimer in 
SDS-polyacryamide gel  electrophoresis (SDS-PAGE)  if samples  are  not  boiled 
(30). Cell lysates were therefore prepared without prior boiling or reduction, in 
a  sample  buffer containing 0.2%  SDS,  and  were electrophoresed, blotted, and 
reacted  with  HB10A  according  to  standard  procedures.  As  shown  in  Fig.  6, 
about two-thirds of the HB 10A binding in wild-type 8.1.6 cells was to the HLA- 
DR dimer, and the remainder was to the DR/3 monomer. In contrast, under the 
same conditions no dimer could be seen from any of the 16.23 epitope mutants, 
and the amount of DR/3 monomer was increased in proportion to the reduction 
in  dimer.  These results  indicate  that  the  lesions  in  the  16.23  epitope  mutants 
FIGURE 5.  Western blot analyses of DR a and/3 protein subunits in boiled NP-40 extracts of 
expression-defective mutants. The ratios of DR a and/3 band intensities of mutants to 8.1.6, 
normalized to actin, respectively are: 9.4.3, 0.05 and 0.41; 9.12.3, 0.11 and  0.60; 9.22.3, 
<0.04 and <0.04; 9.29.3, 0.61 and 0.60. 1202  HLA  CLASS  11  POINT  MUTANTS 
FIGURE  6,  Western blot analysis of HLA-DR3 protein dimer and DR t3 monomer in unboiled 
NP-40 extracts of epitope-defective mutants. 
have reduced the strength of the  DR subunit association, rendering the DR3 
dimer more susceptible to dissociation by dilute SDS. However, since cell surface 
binding of the conformation-sensitive antibody VI. 15 is reduced at most by 30% 
in the epitope mutants, the effect of the mutational lesion on HLA-DR3 subunit 
association,  transport,  or  conformation  in  the  intact  cell  under  physiologic 
conditions cannot be large in any of the mutants. The fact that the majority of 
the  HB10A  binding in the  Western blot of 8.1.6  is  to dimer whereas,  in  the 
epitope mutants, no dimer is seen under the same conditions, suggests that most 
of the dimer reactive with HB10A contains the DR/3 chain bearing the  16.23 
epitope;  otherwise, dimer that formed with  the  second,  unaltered /3 chain,  if 
present in appreciable amounts, should have been apparent in the Western blots 
from the epitope mutants. 
Discussion 
In this report we describe two broad classes  of HLA class  II mutants, those 
which express relatively normal amounts of HLA-DR3 at the cell surface, but 
with an altered structure, and those which express reduced amounts of HLA- 
DR3.  The lesions in  the latter, taken together, affect a  variety of steps in the 
pathway leading to class  II gene expression. Characterization of the lesions in 
these mutants therefore offers an approach to elucidating steps involved in class 
II  regulation.  We  have  previously (10-12)  described  a  mutant,  6.1.6,  which 
expresses virtually no class II gene products because of a defect in a transactive 
regulator of transcription of all class II genes. The expression-defective mutants 
described here all differ from 6.1.6 in that they only affect expression of HLA- 
DR o~ or/3. Some of the expression-defective mutants have lesions analogous to 
those found in  mouse strains that are defective in expression of I-E (31),  the 
murine  homolog of HLA-DR,  whereas  others  have  defects  in  class  II  gene 
expression that have not been previously described. 
Among the latter are mutants 9.4.3 and 9.15.3, which have severe reductions 
in HLA-DR3 protein and DR/3 mRNA levels accompanied by demethylation of 
a  CpG  in  one  of the  DR  /3  genes.  We  have  previously noted  (28)  a  strong 
correlation between class II gene nonexpression and demethylation of CpG sites 
in or around class II genes in isogenic pairs of cells, one of which expresses class PIOUS  ET  AL.  1203 
II genes and the other of which does not. The demethylation of only one of the 
DR/3 genes in 9.4.3 and 9.15.3  is in contrast to the demethylation seen in all 
class II genes in 6.1.6; it is consistent with the more limited lesions in 9.4.3 and 
9.15.3, which appea~ to affect transcription of a single DR/3 gene. The selective 
nature of the transcriptional defect in 9.4.3 and 9.15.3, limited to a single DR/3 
gene,  makes it likely that the  mutational lesions are  in  an element cis  to  the 
affected DR /3 gene, rather than in a  transactive factor, as in 6.1.6.  Such a  cis 
lesion might be in a promoter or enhancer. Evidence has recently been obtained 
for an enhancer in the 5' end or flanking region of the I-E/3 gene, the murine 
homolog of DR/3 (32, 33). By sequencing genomic clones of the affected genes 
and the 5'  flanking regions of transcription-defective mutants such as 9.4.3,  it 
should be possible to define the cis sequences involved in regulation of transcrip- 
tion of HLA class II genes. 
Whereas the lesions in mutants 9.4.3 and 9.15.3 are at the level of transcrip- 
tion, those in 9.12.3, 9.20.3, and 9.27.3 appear to affect different posttranscrip- 
tionai steps. In the HLA-DR3 mutant 9.12.3, the reduced level of normal DR a 
mRNA and the appearance of a  new, larger mRNA species hybridizing to the 
DR o~ probe are most easily explained by a nucleotide substitution that alters the 
processing of the DR  a  transcript by creating an alternative splice site.  These 
alterations in DR a  mRNA in 9.12.3 closely resemble those reported by Mathis 
et al. (31) in I-E ~ mRNA from the B10.M strain of mouse. Mutant 9.20.3, which 
has a  reduced level of DR/3 mRNA without a  change in methylation of DR/3 
genes, appears to have a  lesion affecting DR /3 mRNA processing or stability. 
Mutant  9.27.3  has  normal  levels of DR  a  and  /3  mRNA,  but  in  preliminary 
experiments appears to have reduced levels of DR ot and/3 subunits. These could 
result from a nonsense or cap site mutation or one affecting a posttranslational 
step, such as the association of DR o~ and/3 subunits to form dimers. 
The analysis of mutants such as those described here offers additional insights 
into issues  concerning the class  II region. Among these issues are which of the 
several DR/3 genes are expressed, and how specific class II genes are related to 
the specific class  II gene products recognized by mAb.  Mutant 9.4.3  provides 
information on both the relative quantities of the different DR/3 genes expressed 
per haplotype as well as the gene coding for the gene product recognized by 
antibodies 16.23,  L243, and VI.15.  Mutant 9.4.3  has a  methylation change in 
only one DR/3 gene, and has lost ~94% of the mRNA hybridizing to the DR fl 
probe, indicating that most of the mRNA hybridizing to the DR/3 cDNA gene 
probe is transcribed from one DR/3 gene. The reduction in binding of 16.23, 
VI.15, and L243 in 9.4.3 makes it likely that these antibodies bind only to the 
product of the DR fl gene affected in 9.4.3. On the other hand, antibody HB 10A 
binding is only reduced by two-thirds in 9.4.3; therefore, HB10A reacts with the 
same DR /3 chain as do  16.23,  VI.15, and L243, but it also must react with a 
second/3 chain not affected in 9.4.3.  The deletion of the DR a  gene in 9.22.3 
virtually eliminates HB10A binding; therefore, the second/3 chain reactive with 
HB10A must be a DR fl chain. Assuming that the residual binding of ~10% for 
16.23, VI.15, and L243 on 9.4.3 reflects the remaining expression of the major 
DR fl chain, the second DR/3 chain appears to be only 20% as abundant as the 
major DR fl chain. Unlike binding by the other monomorphic antibodies, LKT 1204  HLA  CLASS  II  POINT  MUTANTS 
and L227 binding are only reduced by 50-60% by the DR a  deletion in 9.22.3, 
suggesting that these antibodies react with non-DR as well as DR/3 chains. The 
complete loss of LKT and  L227 binding in a  DR null mutant that was  subse- 
quently selected for and  had  lost  DP  expression indicates that the non-DR /3 
chain to which  LKT and L227  bind is  HLA-DP. This conclusion concerning 
L227 agrees with that based on studies of deletion mutants (34), but differs from 
that based on immunoprecipitation experiments (35). 
Mutants with single amino acid substitutions in the epitope recognized by the 
antibody used for selection have proven useful in primary sequence mapping of 
an alloepitope of an HLA class I molecule (36, 37) as well as in functional studies 
(38, 39).  Comparable class II mutants can be used for similar purposes. The fact 
that  16.23  binding is  lost in mutants such as 9.5.3  whereas VI.15,  L243, and 
HB 10A binding remains essentially normal, together with the evidence presented 
above that  16.23,  VI.15,  and  L243  bind to the same molecule, indicates that 
mutants such as  9.5.3  are  in  fact epitope defective. A  striking feature of the 
epitope-defective mutants is that they all have reductions in the strength of their 
HLA-DR3 subunit associations. One explanation for this similarity among the 
epitope mutants is that they all derive from the same mutational event, but this 
seems unlikely based on the finding of a minimum of five distinct phenotypes in 
the eight expression-defective mutants, and on previous data from a comparable 
EMS  mutagenesis and  HLA-A2  selection,  which  yielded a  minimum of nine 
different phenotypes (including at least four different epitope mutants) of 15 
mutants studied. If the epitope-defective mutants arose from different events, 
then the fact that all are affected in their HLA-DR3 subunit associations suggests 
two interesting alternatives. Either changes in the several amino acids composing 
the  16.23  epitope have a  high  likelihood of affecting dimer stability or,  con- 
versely,  the  16.23  epitope  is  perturbed  by  amino  acid  substitutions  broadly 
distributed throughout one or both subunits. 
DNA sequencing of the epitope mutants offers a way of identifying which of 
the several  DR  ~  genes  present  on  an  HLA baplotype is  the expressed  gene 
bearing the HLA-DR3 epitope recognized by 16.23, and of locating the amino 
acids comprising the epitope. These studies should contribute to an understand- 
ing of the associations of HLA-DR3 with autoimmune diseases. Recently (40), 
murine alloantibody-selected class II mutants have been found to be altered in 
their ability to present soluble antigen. Human Epstein-Barr virus-transformed 
B cell lines are able to present soluble antigen in a  class  II-restricted manner 
(41).  These  mutants thus  should provide  a  means of assessing  the  effects of 
specific amino acid substitutions in class II molecules on antigen presentation in 
human cells. 
Summary 
Point mutations that affect HLA-DR structure or expression have not previ- 
ously been described. In the present study, we isolated such mutants by immu- 
noselection of an ethyl methanesulfonate-mutagenized HLA-DR3 cell line with 
an anti-HLA-DR3 monoclonal antibody, 16.23. To facilitate analysis, we used a 
parent cell  line with a preexisting deletion of one haplotype encompassing DR 
and DQ o~ and/3. The selection yielded two sets of mutants, one with defects in PIOUS  ET  AL.  1205 
DR3 structure, the other with defects in different steps leading to DR expression. 
Of  the  expression-defective  mutants,  one  had  undergone  a  second  deletion 
removing the remaining DR ~  gene but no other class II genes. It had a normal 
abundance of DR/3 mRNA but had lost binding of DR monomorphic antibodies, 
indicating that  DR/3 chains do not form noncognate dimers. A  second mutant 
had  an  abnormally  large  DR  o~  mRNA,  probably  resulting  from  a  splice  site 
mutation. Several mutants had marked reductions in DR fl mRNA levels; in two 
of these, the lesion appeared to be transcriptional because the reduction in DR 
/3 mRNA  was paralleled by an altered methylation pattern  of one of the DR/3 
genes. Other expression-defective mutants had different posttranscriptional de- 
fects. Some of the mutations were similar to those that have been found in mouse 
strains  defective  in  I-E  expression,  whereas  others  have  no  known  natural 
counterpart.  The  matrix  of  reactivities  of  anti-HLA  class  II  monomorphic 
antibodies with these and similar mutants allowed us to define the gene products 
recognized by these antibodies. 
A set of seven mutants were "epitope defective," that is, they expressed normal 
or near normal levels of HLA-DR3 but no longer bound  16.23.  Unexpectedly, 
each of the epitope mutants  had decreased DR dimer stability. These mutants 
should be useful in localizing the DR3 alloepitope and in elucidating its contri- 
bution as a restriction element in the presentation of soluble antigen to immune 
T  cells. 
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Erlich and B. Mach for gifts of cloned HLA genes; and Dan Hill for preparation of the 
manuscript. 
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